At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,191 enrolled
Drug / intervention
Aliskiren +4 moredrug
Likely dose
Aliskiren 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An 8 Week, Double-blind, Randomized, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate to Severe Hypertension
In Brief
A Phase 3 clinical trial evaluating Aliskiren, Amlodipine, and 2 other interventions for Hypertension. Completed, enrolled 1,191 participants across 12 sites in 12 countries.
Detailed Summary
This study evaluated the efficacy (blood pressure lowering effect) and safety of aliskiren/amlodipine/hydrochlorothiazide in patients with moderate to severe hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesAustralia, Canada, Denmark, Germany, Israel, Italy, Latvia, Lithuania, Romania, Sweden, Turkey (Türkiye), United States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
First PostedOct 2008
Primary CompletionAug 2009
TodayJul 2026
First PostedOct 3, 2008
Enrollment StartSep 1, 2008
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.7 years ago
Interventions
Aliskirendrug
150 and 300 mg tablets
Amlodipinedrug
5 and 10 mg capsules
Hydrochlorothiazide (HCTZ)drug
12.5 and 25 mg capsules
Placebodrug
tablet
Placebodrug
capsules